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Background: Left ventricular (LV) diastolic dysfunction is frequently observed in patients with type 2 diabetes.
Dipeptidyl peptidase-4 inhibitor (DPP-4i) attenuates postprandial hyperglycemia (PPH) and may have cardio-protective
effects. It remains unclear whether DPP-4i improves LV diastolic function in patients with type 2 diabetes, and, if so, it is
attributable to the attenuation of PPH or to a direct cardiac effect of DPP-4i. We compared the effects of the DPP-4i,
sitagliptin, and the alpha-glucosidase inhibitor, voglibose, on LV diastolic function in patients with type 2 diabetes.
Methods: We conducted a prospective, randomized, open-label, multicenter study of 100 diabetic patients with LV
diastolic dysfunction. Patients received sitagliptin (50 mg/day) or voglibose (0.6 mg/day). The primary endpoints were
changes in the e’ velocity and E/e’ ratio from baseline to 24 weeks later. The secondary efficacy measures included
HbA1c, GLP-1, lipid profiles, oxidative stress markers and inflammatory markers.
Results: The study was completed with 40 patients in the sitagliptin group and 40 patients in the voglibose group.
There were no significant changes in the e’ velocity and E/e’ ratio from baseline to 24 weeks later in both groups.
However, analysis of covariance demonstrated that pioglitazone use is an independent factor associated with changes
in the e’ and E/e’ ratio. Among patients not using pioglitazone, e’ increased and the E/e’ ratio decreased in both the
sitagliptin and voglibose groups. GLP-1 level increased from baseline to 24 weeks later only in the sitagliptin group
(4.8 ± 4.7 vs. 7.3 ± 5.5 pmol/L, p < 0.05). The reductions in HbA1c and body weight were significantly greater in the
sitagliptin group than in the voglibose group (−0.7 ± 0.6 % vs. −0.3 ± 0.4, p < 0.005; −1.3 ± 3.2 kg vs. 0.4 ± 2.8 kg,
p < 0.05, respectively). There were no changes in lipid profiles and inflammatory markers in both groups.
Conclusions: Our trial showed that sitagliptin reduces HbA1c levels more greatly than voglibose does, but that neither
was associated with improvement in the echocardiographic parameters of LV diastolic function in patients with
diabetes.
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Diabetes mellitus is a major risk factor for heart failure
(HF), especially HF with preserved ejection fraction
(HFPEF) development [1, 2]. Diabetes and HF commonly
coexist, and together these conditions are associated with
increased morbidity and mortality compared with either
condition alone [3–7]. A recent study in Olmsted County,
MN, USA, has shown that the prevalence of diabetes in
HF patients has increased markedly over time (3.8 % per
year) [8]. An angiotensin-converting enzyme inhibitor
(ACEi) or an angiotensin receptor blocker (ARB) is effect-
ive in treating HF as well as reducing insulin resistance in
patients with diabetes [9]. Other therapeutic strategies are
lacking the same level of effectiveness. Studies have shown
that elevated HbA1c is a marker of increased risk of devel-
oping HF and, therefore, poor glycemic control may be
causally related to the development of HF [10, 11]. How-
ever, the optimal treatment of hyperglycemia in patients
with diabetes to reduce the progression of HF has not
been well studied.
Recent studies have shown that dipeptidyl peptidase-4 in-
hibitor (DPP-4i), which increases the circulating glucagon-
like peptide-1 (GLP-1) level, attenuates postprandial
hyperglycemia and may have cardio-protective effects
[12–14]. In a diabetic rat model, Shigeta et al. [15] demon-
strated that DPP4 inhibition reverses left ventricular (LV)
diastolic dysfunction via membrane-bound DPP4/stromal
cell-derived factor-1α-dependent local actions on angio-
genesis and circulating DPP4/GLP-1-mediated inotropic
actions. Using HF-model rats, dos Santos et al. [16] re-
ported that sitagliptin (40 mg/kg) administered for 6 weeks
exhibited a significant improvement in cardiac contraction
and reduction in LV end-diastolic pressure and chamber
stiffness. Small pilot studies of GLP-1 have shown poten-
tial promise in the treatment of HF patients [17, 18]. How-
ever, it remains unknown whether DPP-4i improves LV
diastolic function in patients with type 2 diabetes, and, if
so, whether the effect is attributable to the attenuation of
postprandial hyperglycemia or to the direct cardiac effect
of DPP-4i.
Methods
We conducted a randomized, prospective, open-label,
multicenter study to compare the effects of sitagliptin, a
DPP-4 inhibitor, and voglibose, an alpha GI, on LV dia-
stolic function. The assessment was done by Doppler
echocardiography in patients with type 2 diabetes at 13
sites between January 2011 and January 2013.
Study population
Our study population consisted of outpatients with type
2 diabetes from 20 to 85 years of age with LV diastolic
dysfunction (LV ejection fraction >50 %, mitral annular
early diastolic velocity (e’) <8 cm/s or the ratio of mitralinflow velocity to e’ velocity (E/e’ ratio) >15). These
patients had not achieved the targets for glycemic control
with diet, exercise, sulfonylurea, metformin or pioglita-
zone treatments. We recruited 100 patients with 50
receiving sitagliptin (50 mg/day) treatment and 50 vogli-
bose (0.6 mg/day). The doses of the two drugs used in this
study are the recommended therapeutic doses for
Japanese patients who are covered by the Japanese
National Health Insurance.
The exclusion criteria were: patients being treated with
insulin, alpha GI or glinide; and/or exhibited any of the
following: type 1 diabetes, HbA1c ≥9.0 % (75 mmol/
mol), systolic blood pressure ≥160 mmHg and serum
creatinine ≥1.5 mg/dL at baseline, myocardial infarction
(MI) or stroke within the previous 24 weeks, significant
LV hypertrophy at baseline (LV wall thickness ≥13 mm),
atrial fibrillation at baseline, and significant valve dis-
eases (more than or equal to moderately severe valve
diseases). The study protocol was approved by the Ethics
Committee of Okayama University Graduate School of
Medicine, Dentistry, and Pharmaceutical Sciences, and
of each hospital. Written informed consent was obtained
from all patients before any study procedure.
Study protocol
The patients were followed for at least 8 weeks to observe
that the treatment goal by diet, exercise, sulfonylurea,
metformin or pioglitazone was not being achieved. The
patients were prospectively and randomly assigned to add-
itional treatment with either sitagliptin (50 mg/day) or
voglibose (0.6 mg/day) for at least 24 weeks (Fig. 1). We
chose a stratified block randomization. Stratified block
randomization was computer-generated and done by use
of a web-based system (Nouvelle Place Inc. [http://
www.n-place.co.jp/]). Patients were stratified according to
age (≥ or < 65 years old), HbA1c (≥ or < 7 %), e’ (≥ or <
6.0 cm/s), and combined use of thiazolidinediones.
Standard echocardiography was performed at the base-
line and after 24 weeks of treatment. From the mitral
flow velocity pattern, measurements were taken of peak
velocities of E and A waves, the ratio of their peak vel-
ocities (E/A ratio) and deceleration time of the E wave.
Spectral pulsed-wave Doppler tissue interrogation of
longitudinal mitral annular velocity was recorded
throughout the cardiac cycle at the septal annulus in the
apical four-chamber view. The peaks of myocardial
systolic apically directed velocity (s’) and early diastolic
velocity (e’) were measured.
Additional exploratory analyses including changes in
the chamber dimensions and LV ejection fraction were
assessed. LV mass was measured by using the American
Society of Echocardiography-recommended formula
and the end-systolic left atrial volume was measured by
using the ellipsoid model [19]. Both values were
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graphic studies were done when patients were clinically
stable on treatment.Measurements of biochemical parameters
The following parameters were measured at baseline and
after 24 weeks of treatment: complete blood count, liver
function test including measurement of AST, ALT and
LDH, renal function test including measurement of
BUN, creatinine, Na, K and Cl, HbA1c, gastric inhibitory
peptide (GIP), GLP-1, C-peptide, CD34, lipid profile in-
cluding total cholesterol, triglyceride, and high-density
lipoprotein (HDL-C), adiponectin, oxidative stress markers
including malondialdehyde-modified low density lipopro-
tein (MDA-LDL) and urine 8-hydroxy-2′-deoxyguanosine
(8-OHdG), inflammatory markers including high-sensitive
C-reactive protein (hs-CRP) and pentraxin-3 (PTX-3), and
estimated glomerular filtration rate (eGFR). HbA1c levels
were measured using high-performance liquid chroma-
tography. The number of CD34+ cells was determined
by flow cytometry using fluorescein isothiocyanate-
labeled CD45 and phycoerythrin (PE)-labeled CD34
antibodies (BD Biosciences, Franklin Lakes, NJ, USA).
eGFR (mL/min/1.73 m2) was determined by the modified
Modification of Diet and Renal Disease study formula
(MDRD) for Japanese: eGFR = 194 × (age-0.287) × (serum
creatinine-1.094) × (0.739 if female). Brain natriuretic pep-
tide (BNP) concentrations were measured using a com-
mercially available specific radioimmunoassay for human
BNP (Shiono RIA BNP assay kit, Shionogi Co., Ltd., Osaka,
Japan), respectively. Antihypertensive, antihyperlipidemic
and antidiabetic drugs were not changed and anti-oxidantFig. 1 The study’s workflow. Twenty patients were excluded including 6 w
protocol violation (not meeting inclusion criteria, 12 patients; LVEF < 50 %, 1;
study was completed in 77 (77 %) of the patients; 38 received sitagliptin anddrugs including vitamin C and E were not added through-
out the study period.
Endpoints
The primary endpoints were changes in e’ and E/e’ ratio
from baseline to the end of follow-up. The secondary
efficacy measures included changes in glucose, HbA1c,
GIP, GLP-1, C-peptide, CD34, lipid profile, oxidative stress
markers including MDA-LDL and 8-OHdG, inflammatory
markers including hs-CRP and PTX-3 and eGFR, and any
adverse events.
Statistical analysis
All of the results are expressed as mean ± SD or as pro-
portions (%). We assumed that e’ increased by 1.0 cm/s in
the sitagliptin group and 0.2 cm/s in the voglibose group
with a standard deviation of 1.5 cm/s [20]. A minimum
sample size of 57 participants in each group was required
to detect statistical differences in e’ with a power of 80 %
and α error of 5 %. The effects of sitagliptin and voglibose
on LV diastolic function were compared using a paired t-
test. Differences in age, sex, weight, body mass index and
blood pressure were compared using the Student’s t-test.
Categorical variables were compared using χ2 test and
Fisher’s exact test when appropriate. Differences in sec-
ondary efficacy measures between baseline and 24 weeks
were compared using a paired t-test. A value of p < 0.05
was set as the threshold for significance. The effects of
sitagliptin and voglibose on LV diastolic function (e’ and
E/e’ ratio) were assessed by analysis of covariance
(ANCOVA) after adjustment for covariates that included
baseline e’ and E/e’ ratio, age, sitagliptin/voglibose use and
concomitant thiazolidinedione use. Multivariate analysis ofho were lost to follow-up, 1 who declined to participate and 13 for
under medical treatment with high-dose sulfonylurea). The follow-up
39 voglibose






Age, y 67.8 ± 10.5 66.7 ± 9.8 0.654




Body mass index, kg/m2 27.7 ± 4.1 25.7 ± 4.3 0.038
Abdominal girth, cm 88.7 ± 14.3 85.9 ± 15.6 0.469
Current smoking 6(15) 4(10) 0.762
Regular alcohol drinkers 13(33) 17(43) 0.489
NYHA functional class
Class I, n (%) 17(43) 17(43) 1.000
Class II, n (%) 23(58) 22(55)
Class III, n (%) 0(0) 1(3)
Grades of Diastolic Dysfunction
0 1 (2.6) 3 (7.5) 0.0987
1 31 (79.5) 34 (85.0)
2 7 (17.9) 3 (7.5)
Diabetes complication+ 7(18) 3(8) 0.311
Diabetic retinopathy 4(10) 2(5) 0.675
Diabetic nephropathy 3(8) 0(0) 0.241
Diabetic neuropathy 2(5) 0(0) 0.494
Hypertension 37(93) 32(80) 0.193
Hyperuricemia 31(78) 31(78) 1.000
Hyperlipidemia 5(13) 4(10) 1.000
Renal disturbance 7(18) 1(3) 0.057
Mean eGFR 74.8 ± 21.7 70.5 ± 15.3 0.304
Cerebrovascular disease 3(8) 1(3) 0.615
Myocardial infarction 5(13) 2(5) 0.432
Peripheral artery disease 3(8) 1(3) 0.615
Anti-diabetic drugs
Pioglitazone 14(35) 18(45) 0.494
Sulfonylurea 6(15) 3(8) 0.481
Metformin 7(18) 1(3) 0.057
α-GI 1(3) 0(0) 1.000
Antihypertensive drugs
ARB 28(70) 27(68) 1.000
Calcium channel blocker 26(65) 22(55) 0.494
Diuretics 15(38) 10(25) 0.335





Aldosterone antagonist 2(5) 1(3)
Antihyperlipidemic drugs
Table 1 Baseline clinical characteristics (Continued)
Statins 24(60) 22(55) 0.821
Fibrate 2(5) 2(5) 1.000
Ezetimibe 5(13) 6(15) 1.000
Eicosapentaenoic acid 5(13) 2(5) 0.432
Antiplatelet agent 10(25) 12(30) 0.803
Nitrates 1(3) 1(3) 1.000
Allopurinol 1(3) 4(10) 0.359
Uricosuric agents 0(0) 1(3) 1.000
Values are means ± SD, number of patients (%), or median (95 % confidencel
Interval). The continuous variables were compared using Student’s t-test, the
categorical variables were compared using Fisher’s exact test, grades of
diastolic dysfunction was compared using Cochran-Armitage trend test, and
the duration of diabetes was compared using the Wilcoxon rank sum test
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and E/e’ ratio levels was performed. All analyses were per-
formed using SAS 9.3 (SAS Institute Inc., Cary, NC, USA).Results
Baseline characteristics
One hundred patients (59 men and 41 women, aged
67.1 ± 9.6 years) with type 2 diabetes were enrolled in
this study. Fifty patients received sitagliptin (50 mg/day)
treatment and 50 patients received voglibose (0.6 mg/
day) treatment. Twenty patients were excluded including
7 who were lost to follow-up and 13 for protocol viola-
tion (not meeting inclusion criteria, 6 patients;LV ejec-
tion fraction <50 %, 1; under medical treatment with
high-dose sulfonylurea.). The follow-up study was com-
pleted in 80 (80 %) of the patients; 40 received sitagliptin
and 40 voglibose (Fig. 1). Baseline clinical characteristics,
including age, sex, body mass index and the type of anti-
diabetic and antihypertensive medication are shown in
Table 1. No patients died, developed cardiovascular









Baseline at 0W 5.6 ± 1.3 5.5 ± 1.1 p = 0.664
at 24W 5.8 ± 1.3 5.8 ± 1.1 p = 0.997
Δe’: 24W-0W 0.2 ± 1.1 0.3 ± 0.9 p = 0.702
E/e’
Baseline at 0W 12.8 ± 4.3 11.6 ± 2.1 p = 0.109
at 24W 12.4 ± 3.4 11.1 ± 2.7 p = 0.060
ΔE/e’: 24W-0W -0.3 ± 2.5 -0.5 ± 2.3 p = 0.804
Values are means ± SD
W weeks
Fig. 2 Changes in e’ and E/e’ between baseline and 24 weeks later. The e’ velocity and E/e’ ratio were comparable between sitagliptin and
voglibose groups at baseline. The e’ velocity and E/e’ ratio showed no changes between baseline and a mean of 24 weeks later in both groups.
There was also no significant difference in the magnitude of the changes in e’ velocity and E/e’ ratio between the two groups. e’, mitral annular
early diastolic velocity; E/e’, ratio of mitral inflow velocity to e’ velocity; W, weeks
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The e’ velocity and E/e’ ratio were comparable between
the sitagliptin and voglibose groups at baseline. The e’
velocity and E/e’ ratio in both groups showed no changes
between baseline and after a mean of 24 weeks (e’: sitaglip-
tin +0.2 ± 1.1 cm/s and voglibose +0.3 ± 0.9 cm/s; E/e’: sita-
gliptin −0.3 ± 2.5 and voglibose −0.5 ± 2.3). There was also
no difference in magnitude of the changes in e’ velocity and
E/e’ ratio between the two groups (Table 2 and Fig. 2).
The effects of sitagliptin and voglibose on LV diastolic
function (e’ and E/e’ ratio) were assessed by ANCOVA
after adjustment for covariates that included baseline e’
and E/e’ ratio, age, sitagliptin/voglibose use and con-
comitant thiazolidinedione use. ANCOVA demonstrated
that pioglitazone use is an independent factor associated
with changes in e’ and E/e’ ratio (Table 3). Among
patients not using pioglitazone, e' increased and E/e’
ratio decreased in both sitagliptin and voglibose groups
(e’: sitagliptin +0.5 ± 1.1 cm/s and voglibose +0.5 ± 0.9 cm/
s; E/e’: sitagliptin −1.0 ± 2.7 and voglibose −0.8 ± 2.4).
Multivariate analysis of factors related to changes
from baseline to 24 weeks in e’ and E/e’ ratio levelsTable 3 Factors affecting e’ and E/e’ at week 24a
Dependent variable Independent variable Esti
e’ (24W) e’ (0W) 0.52
Sitagliptin/Voglibose -0.0
Age — yr -0.0
without/with TZD 0.54
E/e’ (24W) E/e’ (0W) 0.61
Sitagliptin/Voglibose 0.68
Age — yr 0.02
without/with TZD -1.4
95 % CIs and P values were calculated with the use of analysis of covariance (ANCO
aCI denotes confidence intervalshowed for e’, without/with thiazolidinedione was not
statistically significant only if adiponectin was added in
the model, and for E/e’, without/with thiazolidinedione
was statistically significant for all models, which implies
that without/with thiazolidinedione could be an inde-
pendent factor associated with changes in the E/e’ ratio
(Table 4).
Secondary efficacy measures
The GLP-1 level increased from baseline to 24 weeks
later in the sitagliptin group but not in the voglibose
group (4.8 ± 4.7 pmol/L vs. 7.3 ± 5.5 pmol/L, p < 0.05, re-
spectively). The decreases in HbA1c and body weight
were significantly greater in the sitagliptin group than in
the voglibose group (−0.7 ± 0.6 % vs. −0.3 ± 0.4 %, p <
0.005 and −1.3 ± 3.2 kg vs. 0.4 ± 2.8 kg, p < 0.05, respect-
ively). There were no significant differences in the changes
in C-peptide, lipid profile, oxidative stress marker and in-
flammatory marker between the two groups (Table 5 and
Fig. 3). In only the sitagliptin group, and not the voglibose
group, did the systolic blood pressure and LV septal wall
thickness decrease 24 weeks later (135 ± 16 mmHg vs.mate 95 % CI P value
5 0.309 0.742 <0.0001
47 -0.455 0.362 0.821
28 -0.054 -0.003 0.032
7 0.130 0.965 0.011
5 0.471 0.758 <0.0001
8 -0.239 1.615 0.144
4 -0.025 0.072 0.334
11 -2.339 -0.483 0.003
VA)
Table 4 Multivariate analysis of factors related to changes from baseline to week 24 in e’ and E/e’ ratio levelsa
Model e’ [cm/s] E/e’
Change from baseline P valueb R2 Change from baseline P valueb R2
Beta (95 % CI) Beta (95 % CI)
Model1—Primary model 0.500 0.609
Baseline 0.525 (0.309 to 0.742) <.0001 0.615 (0.471 to 0.758) <.0001
Sitagliptin/Voglibose -0.047 (-0.455 to 0.362) 0.8206 0.688 (-0.239 to 1.615) 0.1436
Age—yr -0.028 (-0.054 to -0.003) 0.0317 0.024 (-0.025 to 0.072) 0.3335




Baseline 0.520 (0.298 to 0.742) <.0001 0.603 (0.456 to 0.750) <.0001
Sitagliptin/Voglibose -0.069 (-0.504 to 0.365) 0.7509 0.683 (-0.271 to 1.636) 0.1576
Age—yr -0.025 (-0.052 to 0.002) 0.0739 0.013 (-0.037 to 0.064) 0.5964
Female/Male 0.243 (-0.195 to 0.681) 0.2718 -1.114 (-2.092 to -0.137) 0.0261
BMI (0W) 0.033 (-0.019 to 0.084) 0.2140 -0.037 (-0.155 to 0.081) 0.5306
SBP (0W) -0.005 (-0.020 to 0.011) 0.5454 -0.002 (-0.036 to 0.031) 0.8917
Pulse (0W) -0.003 (-0.025 to 0.019) 0.7882 0.022 (-0.028 to 0.071) 0.3911
Without/with TZD 0.662 (0.216 to 1.108) 0.0042 -1.732 (-2.711 to -0.753) 0.0007
Model3—Add complicationsb 0.518 0.626
Baseline 0.487 (0.253 to 0.721) <.0001 0.584 (0.425 to 0.744) <.0001
Sitagliptin/Voglibose 0.018 (-0.426 to 0.462) 0.9362 0.642 (-0.331 to 1.615) 0.1922
Age—yr -0.031 (-0.057 to -0.004) 0.0228 0.030 (-0.020 to 0.081) 0.2389
Diabetes complication -0.395 (-1.038 to 0.247) 0.2238 0.721 (-0.799 to 2.241) 0.3473
Hypertension 0.202 (-0.410 to 0.814) 0.5131 -0.527 (-1.908 to 0.854) 0.4491
Hyperlipidemia 0.219 (-0.317 to 0.755) 0.4177 -0.886 (-2.086 to 0.313) 0.1450
Renal disturbance -0.219 (-1.000 to 0.562) 0.5780 0.277 (-1.453 to 2.007) 0.7502




Baseline 0.542 (0.314 to 0.770) <.0001 0.615 (0.469 to 0.761) <.0001
Sitagliptin/Voglibose -0.127 (-0.568 to 0.314) 0.5671 0.669 (-0.314 to 1.651) 0.1790
Age—yr -0.023 (-0.053 to 0.006) 0.1220 0.029 (-0.027 to 0.084) 0.3045
WBC (0W) -0.000 (-0.000 to 0.000) 0.7030 0.000 (-0.000 to 0.000) 0.2013
AST (0W) 0.012 (-0.008 to 0.032) 0.2398 0.003 (-0.040 to 0.046) 0.8871
BUN (0W) 0.009 (-0.045 to 0.063) 0.7380 -0.019 (-0.139 to 0.101) 0.7498
Glucagon (0W) -0.001 (-0.012 to 0.010) 0.8296 -0.010 (-0.034 to 0.014) 0.3929
Adiponectin (0W) -0.017 (-0.049 to 0.016) 0.3067 -0.030 (-0.102 to 0.041) 0.4020
IVSTh (0W) -0.192 (-1.847 to 1.463) 0.8175 -1.323 (-5.000 to 2.353) 0.4749
Without/with TZD 0.380 (-0.181 to 0.941) 0.1808 -1.675 (-2.916 to -0.434) 0.0089
Model5—Add adiponectinc 0.511 0.620
Baseline 0.516 (0.299 to 0.732) <.0001 0.623 (0.480 to 0.766) <.0001
Sitagliptin/Voglibose -0.080 (-0.490 to 0.330) 0.6991 0.587 (-0.344 to 1.519) 0.2129
Age—yr -0.025 (-0.051 to 0.001) 0.0637 0.033 (-0.016 to 0.083) 0.1858
Adiponectin (0W) -0.018 (-0.047 to 0.011) 0.2169 -0.046 (-0.112 to 0.019) 0.1610
Without/with TZD 0.388 (-0.099 to 0.876) 0.1169 -1.807 (-2.884 to -0.730) 0.0013
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Table 4 Multivariate analysis of factors related to changes from baseline to week 24 in e’ and E/e’ ratio levelsa (Continued)
Model6—Remove TZD 0.493 0.560
Baseline 0.480 (0.266 to 0.695) <.0001 0.624 (0.472 to 0.777) <.0001
Sitagliptin/Voglibose -0.067 (-0.481 to 0.347) 0.7471 0.566 (-0.429 to 1.561) 0.2605
Age—yr -0.026 (-0.052 to 0.001) 0.0580 0.025 (-0.028 to 0.078) 0.3505
Adiponectin (0W) -0.030 (-0.055 to -0.005) 0.0187 0.010 (-0.050 to 0.070) 0.7331
aThe analysis was performed in the full analysis set, with the use of analysis of covariance, WBC denotes white blood cell, AST aspartate transaminase, BUN blood
urea nitrogen, IVSTh interventricular septum thickness, and TZD thiazolidinedione
bStatistically significant variables (alpha = 0.05) were selected from measured demographics, complications and laboratory variables with the use of two sample
t-tests, according to without/with TZD groups in the full analysis set
cFor e’, without/with TZD was not statistically significant (alpha = 0.05) only if adiponectin was added in the model
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respectively) (Table 6).
Adverse events
Adverse events were observed in 2 patients in the sita-
gliptin group (hypoglycemia and liver dysfunction) and 4
patients in the voglibose group (diarrhea, edema and
gastrointestinal symptoms) (Table 7). Mild hypoglycemia
of a patient in the sitagliptin group improved rapidly
with dose reduction of sulfonylurea. Hospitalizations
because of HF or cardiovascular events were not ob-
served during the study period.
Discussion
This study is the first randomized trial to compare the
impact of glycemic control with sitagliptin and voglibose
on LV diastolic function. Our study demonstrated that
both sitagliptin and voglibose reduce HbA1c, but the
magnitude of reduction of HbA1c was greater in the
sitagliptin group and had a greater increase in the GLP-
1 level. However, despite the improved glycemic control,
the e’ velocity and E/e’ ratio did not show significant im-
provement after 24-week treatment with sitagliptin or
voglibose. There was also no significant difference in the
change in the e’ velocity and E/e’ ratio between the two
groups.
The plasma BNP level, New York Heart Association
(NYHA) functional class and the grades of diastolic func-
tion (ASE/EAE) did not show significant improvement in
either group. Therefore, we conclude that sitagliptin and
voglibose had no impact on e’ velocity or E/e’ ratio in pa-
tients with type 2 diabetes and impaired diastolic function.
Elevated HbA1c has been a marker of increased risk of
developing HF in patients with diabetes [10, 11]. Poor gly-
cemic control and associated hyperglycemia may be caus-
ally related to the development of HF by two mechanisms:
(i) through promotion of atherosclerosis and the ensuing
coronary artery disease [21] and (ii) by development of a
specific diabetic cardiomyopathy by direct damage to the
heart muscle [4, 5]. However, studies examining treatment
strategies of intensive glucose control, such as the UKPDS
and the more recently completed ACCORD andADVANCE studies have not shown statistically significant
reductions in HF events in patients assigned to more in-
tensive glucose control strategies when compared with
those assigned to standard therapy [22–24]. In our study,
the blood glucose level was lowered with sitagliptin and
voglibose though the reduction of HbA1c was greater in
the sitagliptin group, which also had an associated greater
increase in the GLP-1 level. Reduction of body weight and
systolic blood pressure was also found in the sitagliptin
group. These apparently beneficial changes were not,
however, associated with an increase in e’ velocity or with
a reduction in E/e’ ratio in either groups.
Recently, the SAVOR-TIMI 53 trial showed that DPP-
4i may increase the risk of HF [25], which is of concern.
In this trial, more patients in the saxagliptin group than
in the placebo group were hospitalized for HF (3.5 % vs.
2.8 %, according to the 2-year Kaplan–Meier estimates;
hazard ratio 1.27, 95 % CI = 1.07–1.51; p = 0.007). How-
ever, our results indicate that the BNP value, e’ velocity
and E/e’ ratio do not change during sitagliptin use and,
thus, sitagliptin may not be associated with an increased
risk of HF or other serious adverse events. Therefore, we
can conclude that both sitagliptin and voglibose can be
safely used for patients with type 2 diabetes without an
increased risk of worsening LV diastolic function.
Although thiazolidinediones activate the peroxisome
proliferator-activated receptor γ (PPARγ) system and im-
prove insulin sensitivity to reduce cardiovascular events
[26], they are reported to be associated with an increased
risk of HF by augmentation of fluid retention [27]. Inter-
estingly, our data demonstrated that pioglitazone is an
independent factor that affects the temporal changes in
the e’ velocity and E/e’ ratio. The e’ velocity significantly
increased in both sitagliptin and voglibose groups if the
patients who received pioglitazone were excluded. By
contrast, the patients who used pioglitazone showed de-
creased e’ velocity and increased E/e’ ratio at the follow-
up assessment. These data indicate that sitagliptin and
voglibose might improve LV diastolic function by them-
selves, and that pioglitazone may attenuate the beneficial
impact of these drugs on LV diastolic function. However,
it is uncertain whether pioglitazone may worsen HF,
Table 5 Changes in secondary efficacy measures in the sitagliptin and voglibose group
Variable Sitagliptin Voglibose Between-group difference
Mean ± SD P value Mean ± SD P value P value
Glucose
Baseline at 0W 145 ± 58 133 ± 42 0.304
At 24W 127 ± 26 133 ± 27 0.354
24W-0W -23 ± 60 0.047 1 ± 43 0.916 0.083
HbA1c
Baseline at 0W 7.1 ± 0.7 6.9 ± 0.5 0.273
At 24W 6.4 ± 0.4 6.7 ± 0.5 0.026
24W-0W -0.7 ± 0.6 <0.0001 -0.3 ± 0.4 0.0004 0.002
GIP
Baseline at 0W 191 ± 214 159 ± 211 0.517
At 24W 149 ± 161 162 ± 148 0.759
24W-0W -21 ± 226 0.314 0.6 ± 1.6 0.041 0.749
CD34
Baseline at 0W 1.1 ± 0.7 0.9 ± 0.6 0.239
At 24W 1.1 ± 0.5 0.9 ± 0.7 0.160
24W-0W 0.1 ± 0.5 0.435 0.0 ± 0.5 0.772 0.430
Total cholesterol
Baseline at 0W 184 ± 27 185 ± 33 0.944
At 24W 178 ± 29 183 ± 37 0.522
24W-0W -3 ± 30 0.603 0 ± 29 0.991 0.709
Triglyceride
Baseline at 0W 155 ± 107 141 ± 74 0.486
At 24W 132 ± 62 127 ± 72 0.803
24W-0W -15 ± 94 0.391 -13 ± 52 0.190 0.905
HDL-C
Baseline at 0W 51 ± 12 56 ± 16 0.106
At 24W 52 ± 14 53 ± 15 0.930
24W-0W 0.8 ± 7.9 0.551 -3.6 ± 8.2 0.010 0.021
Adiponectin
Baseline at 0W 11.0 ± 8.3 13.3 ± 8.7 0.222
At 24W 11.7 ± 8.8 12.9 ± 7.3 0.528
24W-0W 0.5 ± 1.8 0.092 -0.3 ± 2.9 0.539 0.150
MDA-LDL
Baseline at 0W 106 ± 34 110 ± 37 0.658
At 24W 113 ± 34 109 ± 36 0.591
24W-0W 9 ± 32 0.118 1 ± 38 0.860 0.364
8-OHdG
Baseline at 0W 11.7 ± 7.9 13.5 ± 10.0 0.392
At 24W 11.4 ± 7.4 14.8 ± 14.6 0.221
24W-0W -0.2 ± 10.0 0.903 1.5 ± 16.9 0.596 0.605
hs-CRP
Baseline at 0W 3869 ± 9072 1358 ± 2511 0.099
At 24W 1933 ± 5101 661 ± 691 0.147
Oe et al. Cardiovascular Diabetology  (2015) 14:83 Page 8 of 13
Table 5 Changes in secondary efficacy measures in the sitagliptin and voglibose group (Continued)
24W-0W -1929 ± 6798 0.098 -380 ± 1186 0.059 0.186
PTX-3
Baseline at 0W 1.8 ± 1.0 2.4 ± 2.7 0.206
At 24W 1.5 ± 0.8 1.6 ± 0.8 0.557
24W-0W -0.3 ± 0.7 0.006 -0.3 ± 1.2 0.104 0.974
e-GFR
Baseline at 0W 75 ± 22 71 ± 15 0.304
At 24W 69 ± 19 72 ± 16 0.411
24W-0W -5 ± 12 0.014 0 ± 9 0.903 0.036
BNP, pg/ml
Baseline at 0W 39 ± 48 34 ± 35 0.600
At 24W 40 ± 41 28 ± 24 0.160
24W-0W 1 ± 40 0.923 -5 ± 22 0.164 0.443
GIP gastric inhibitory peptide, GLP-1 glucagon-like peptide-1, CD34 C-peptide, MDA-LDL malondialdehyde-modified low density lipoprotein, 8-OHdG
8-hydroxy-2′-deoxyguanosine, hs-CRP high-sensitive C-reactive protein, PTX-3pentraxin-3, eGFR estimated glomerular filtration rate, BNP B-type
natriuretic peptide
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ized with HF.
An excessive activity of circulating DPP4 was also found
to be independently associated with subclinical LV dys-
function in T2DM patients [28]. Decreased adiponectinFig. 3 Changes in HbA1c, FBS, GLP-1 and body weight between baseline and
significantly greater in the sitagliptin group than in the voglibose group. GLP-
but not in the voglibose group. FBS, fasting blood sugar; GLP-1, glucagon-like
Standardization Program; W, weekslevels were associated with LV diastolic dysfunction in pa-
tients with known or suspected coronary artery disease
[29]. Hibuse et al. reported that serum adiponectin level
was elevated after a three-month treatment with sitaglip-
tin [30], and that abenefical effect of sitagliptin on LV24 weeks later. The decreases in HbA1c and body weight were
1 level increased from baseline to 24 weeks later in the sitagliptin group
peptide-1; HbA1c, hemoglobin A1c; NGSP, National Glycohemoglobin
Table 6 Changes in hemodynamic and echocardiographic parameters in the sitagliptin and voglibose group
Variable Sitagliptin Voglibose Between-group difference
Mean ± SD P value Mean ± SD P value P value
SBP, mmHg
Baseline at 0W 135 ± 16 131 ± 13 0.180
At 24W 128 ± 10 129 ± 15 0.855
24W-0W -7 ± 17 0.022 -2 ± 15 0.496 0.184
DBP, mmHg
Baseline at 0W 74 ± 13 75 ± 10 0.818
At 24W 71 ± 10 75 ± 11 0.108
24W-0W -2 ± 14 0.344 1 ± 10 0.779 0.349
Pulse, b.p.m.
Baseline at 0W 71 ± 11 71 ± 10 0.903
At 24W 69 ± 12 71 ± 11 0.483
24W-0W -1 ± 12 0.653 0 ± 12 0.816 0.625
Body weight
Baseline at 0W 69 ± 10 67 ± 12 0.294
At 24W 68 ± 11 67 ± 13 0.736
24W-0W -1.3 ± 3.2 0.018 0.4 ± 2.8 0.433 0.020
a’, cm/s
Baseline at 0W 8.4 ± 1.6 9.0 ± 1.6 0.110
At 24W 8.1 ± 1.8 9.0 ± 1.6 0.031
24W-0W -0.3 ± 1.7 0.316 0.2 ± 1.4 0.468 0.214
s’, cm/s
Baseline at 0W 6.6 ± 1.1 7.2 ± 1.2 0.019
At 24W 6.8 ± 1.4 7.0 ± 1.1 0.609
24W-0W 0.2 ± 1.4 0.398 -0.2 ± 1.4 0.412 0.237
Dct
Baseline at 0W 234 ± 41 237 ± 39 0.769
At 24W 236 ± 42 233 ± 43 0.765
24W-0W 1 ± 41 0.885 -4 ± 35 0.525 0.604
E velocity, m/s
Baseline at 0W 68 ± 16 62 ± 11 0.048
At 24W 69 ± 14 63 ± 14 0.047
24W-0W 1 ± 10 0.569 0 ± 12 0.879 0.803
A velocity, m/s
Baseline at 0W 82 ± 19 79 ± 18 0.421
At 24W 80 ± 19 74 ± 14 0.150
24W-0W -1 ± 13 0.537 -4 ± 10 0.020 0.299
E/A ratio
Baseline at 0W 0.9 ± 0.3 0.8 ± 0.2 0.424
At 24W 0.9 ± 0.2 0.9 ± 0.3 0.668
24W-0W 0.0 ± 0.2 0.402 0.0 ± 0.2 0.157 0.651
Septal thickness, mm
Baseline at 0W 1.0 ± 0.2 0.9 ± 0.1 0.069
At 24W 0.9 ± 0.1 0.9 ± 0.1 0.502
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Table 6 Changes in hemodynamic and echocardiographic parameters in the sitagliptin and voglibose group (Continued)
24W-0W 0.0 ± 0.1 0.015 0.0 ± 0.1 0.876 0.083
LVEF, %
Baseline at 0W 68 ± 7 71 ± 7 0.209
At 24W 68 ± 6 66 ± 9 0.179
24W-0W 0 ± 8 0.967 -5 ± 8 0.001 0.013
LVMI, g/m2
Baseline at 0W 93 ± 20 85 ± 18 0.085
At 24W 90 ± 17 86 ± 18 0.239
24W-0W -3 ± 13 0.195 1 ± 14 0.551 0.183
LA volume index, ml/m2
Baseline at 0W 27.7 ± 5.9 26.1 ± 7.6 0.346
At 24W 27.7 ± 7.5 26.6 ± 6.3 0.508
24W-0W 0.3 ± 5.0 0.734 0.8 ± 5.6 0.448 0.733
Urine albumin, mg/g/Cr
Baseline at 0W 37 ± 66 31 ± 41 0.603
At 24W 39 ± 94 28 ± 50 0.533
24W-0W -1 ± 50 0.889 -5 ± 30 0.339 0.723
BUN
Baseline at 0W 17 ± 5 16 ± 5 0.760
At 24W 16 ± 3 16 ± 4 0.824
24W-0W 0 ± 3 0.759 0 ± 4 0.740 0.959
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significant increase in serum adiponectin level (0.5 ± 1.8,
p = 0.092) after 24 weeks of treatment with sitagliptin in
this study.
Sitagliptin was associated with an increase in GLP-1,
but voglibose was not. Increased GLP-1 may augment di-
uresis and natriuresis by inhibiting sodium reabsorption
from the proximal renal tubule [31]. GLP-1 induces an
endothelium-dependent vasorelaxation that is dependent
on nitric oxide generation, and this may contribute to
reduced peripheral vascular resistance [32]. Clinical and
experimental studies have shown that DPP-4i has a mod-
erate blood pressure lowering effect [33]. In this study,
sitagliptin significantly lowered SBP, but voglibose did notTable 7 Adverse events
Events Sitagliptin Voglibose
n = 40 n = 40
2 cases (5.0) 4 cases (10.0)
Hypoglycemia 1 (2.5) 0 (0.0)
Diarrhea 0 (0.0) 4 (10.0)
Edema 0 (0.0) 3 (7.5)
Gastrointestinal symptom 0 (0.0) 2 (5.0)
Liver dysfunction 1 (2.5) 0 (0.0)
Total events 2 9
Number of cases (%) is shown(135 ± 16 mmHg vs. 128 ± 10 mmHg, respectively). There
are many studies that demonstrate that reduced systolic
blood pressure is associated with regression of LV mass,
an increase in e’ velocity and a reduction of HF events
[34]. Sitagliptin significantly decreased septal wall
thickness in our study, but did not decrease LVMI
after the 24-week treatment. In the LV hypertrophy rat
model induced by isoproterenol infusion, we previously
demonstrated that vildagliptin treatment was associated
with a reduction in LV mass compared with the control
group [35]. However, the duration of exposure to the
study drugs may not have been long enough to reverse
the effects of years of diastolic dysfunction processes in
patients. The present study does not exclude the possi-
bility of either benefit or increased risk with a longer
duration of sitagliptin therapy.
Owing to the limited sample size, this study is statistically
underpowered
However, there was almost no difference (much less than
0.8 cm/s; assumption) of the change in e’ in the estimated
value between the two groups in this study. So, even if the
target number of cases had been achieved, based on
current datasets, it would be unlikely that a statistically
significant difference would have been obtained.
There are few data about the effect of anti-diabetic
drugs on LV diastolic dysfunction. von Bibra et al.
Oe et al. Cardiovascular Diabetology  (2015) 14:83 Page 12 of 13reported that 16 weeks of treatment with rosiglitazone im-
proved LV diastolic dysfunction evaluated by Doppler
echocardiography (e’; 7.9 cm/s→ 8.9 cm/s, Δe’ = 1.0 cm/s)
[20]. However, it remains unknown whether and how
anti-diabetic drugs including DPP-4i improve LV diastolic
function in patients with type 2 diabetes for now. Further
investigation is needed in this area.
We evaluated diastolic function by measuring the e’
velocity and the E/e’ ratio at the septal side of the mitral
annulus. Nagueh et al. reported that it is preferable to
use the average e’ velocity obtained from the septal and
lateral sides of the mitral annulus. We evaluated the
changes of e’ and the E/e’ (24 W-0 W) in this study, and
our study population excluded patients with LV ejection
fraction < 50 % and myocardial infarction within the pre-
vious 24 weeks, thus single-site (septal e’) measurements
could be applicable.Limitations
We acknowledge several limitations in the present study.
First, although this study was multicenter and random-
ized, the drug participation was open-label. Therefore, we
used a biomarker, e’ velocity, as the primary endpoint. Sec-
ondly, we did not measure plasma DPP-4 activity. The
study of dos Santos et al. [16] reported that positive corre-
lations were observed between plasma DPP-4 activity and
LV end-diastolic pressure and lung congestion in rats.
We did not know whether 50 mg sitagliptin could suc-
cessfully inhibit plasma DPP-4 activity. We used 50 mg of
sitagliptin, which is a standard starting dosage for this
medication in Japan, however, outside of Japan, double
this dose, i.e. 100 mg of sitagliptin, is generally used. A
meta-analysis revealed that, despite the smaller sitagliptin
dose of only 50 mg, a greater HbA1c reduction (−0.99 %
versus placebo) was observed in Japanese than in non-
Japanese patients [36].
Thirdly, because of the small number of patients, we
could not assess whether sitagliptin or pioglitazone can
attenuate HF events in patients, as this study is statisti-
cally underpowered.
Fourth, 6-month treatment might be too short to im-
prove the e’ velocity or E/e’ ratio. Fifth, echocardiographic
studies were performed at each institution by experienced
physicians or sonographers and the results were sent to
the study center for analysis. These processes are close to
those pertaining to real, clinical situations, and diastolic
function echocardiographic parameters were supposed to
be highly reproducible if performed by experts [37], but
inter-institution variability in the examinations may exist
and may have influenced the results of this study.
To estimate the inter-institution variability is difficult
because the number of cases per institution were too
low to evaluate it.Finally, selection criteria of this study population are
strict. It is because we wanted to assess the net effect of
DPP inhibitor on LV diastolic function in this study. It is
necessary to note whether your patient corresponds to
such a patient population or not.
Conclusion
Our trial showed that sitagliptin reduces HbA1c levels
more greatly than voglibose does, but that neither was as-
sociated with improvement in the echocardiographic pa-
rameters of LV diastolic function in patients with diabetes.
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